Robbins LLP Reminds Stockholders of CKPT to Contact the Law Firm for Information About the Checkpoint Therapeutics, Inc. Class Action Lawsuit Robbins LLP is Investigating the Allegations that Checkpoint Therapeutics, Inc. Overstated the Prospects of its Lead Product Candidate, Cosibelimab

CKPT Class Action Alert: Robbins LLP Reminds Stockholders of Checkpoint Therapeutics, Inc. Class Action Robbins LLP is Investigating the Allegations that Checkpoint Therapeutics, Inc. Overstated the Prospects of its Lead Product Candidate, Cosibelimab

Checkpoint Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; June 4, 2024 deadline. Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 10, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Checkpoint Therapeutics, Inc....

Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against Checkpoint Therapeutics, Inc. (CKPT) Robbins LLP is Investigating the Allegations that Checkpoint Therapeutics, Inc. Overstated the Prospects of its Lead Product Candidate, Cosibelimab